Risk of thromboembolism associated with an angiogenesis inhibitor bevacizumab in cancer patients

14559 Background: Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), is widely used in the treatment of many solid tumors. Many clinical studies ...